Audio Journal of Oncology in Advance – March 1st, 2008

Richard Stone

George Canellos

Richard Stone, Dana-Farber Cancer Institute, Boston
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
Data released at the ASH conference show that dasatinib has given durable responses in patients with chronic phase chronic myeloid leukemia for whom imatinib has failed, or who cannot tolerate imatinib. In Atlanta Richard Stone discussed his findings with Derek Thorne, who then asked George Canellos to reflect on them.

Anton Hagenbeek

George Canellos

Anton Hagenbeek, University of Utrecht
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
In patients with advanced-stage follicular non-Hodgkin’s lymphoma the radiolabeled antibody ibritumomab tiuxetan prolonged progression-free survival, according to a study reported at the ASH meeting. Sarah Maxwell spoke to the author Anton Hagenbeek. George Canellos put the data into context.

Charles Hsu

Robert Mayer

Charles Hsu, Johns Hopkins University, Baltimore
COMMENT: Robert Mayer, Dana-Farber Cancer Institute
Patients with resectable pancreas cancer lived longer when treated with adjuvant radiation plus chemotherapy, according to a study reported at the gastrointestinal cancers conference in Orlando. Charles Hsu talked with Peter Goodwin about their findings; Robert Mayer assessed the work.

Pierre Fenaux

Pierre Fenaux, Hôpital Avicenne, Paris
Phase III study results presented at ASH found the hypomethylating agent azacitidine was best for patients with high-risk MDS. Pierre Fenaux gave the details to Derek Thorne, who also heard from George Canellos.

Bart Barlogie

Bart Barlogie, University of Arkansas, Little Rock
The total therapy clinical studies of multiple myeloma reported promising findings to the Hematologic Malignancies Congress in Paris. Bart Barlogie talked with Peter Goodwin about the new data from melphalan-induced tandem autologous transplants with additional thalidomide or bortezomib therapy.